Literature DB >> 11834616

Evidence for an atypical receptor mediating the augmented bronchoconstrictor response to adenosine induced by allergen challenge in actively sensitized Brown Norway rats.

J P Hannon1, B Tigani, C Wolber, I Williams, L Mazzoni, C Howes, J R Fozard.   

Abstract

The bronchoconstrictor response to adenosine is markedly and selectively increased following ovalbumin (OA) challenge in actively sensitized, Brown Norway rats. We present a pharmacological analysis of the receptor mediating this response. Like adenosine, the broad-spectrum adenosine receptor agonist, NECA, induced dose-related bronchoconstriction in actively sensitized, OA-challenged animals. In contrast, CPA, CGS 21680 and 2-Cl-IB-MECA, agonists selective for A(1) A(2A) and A(3) receptors, respectively, induced no, or minimal, bronchoconstriction. Neither the selective A(1) receptor antagonist, DPCPX, nor the selective A(2A) receptor antagonist, ZM 241385, blocked the bronchoconstrictor response to adenosine. MRS 1754, which has similar affinity for rat A(2B) and A(1) receptors, failed to block the bronchoconstrictor response to adenosine despite blockade of the A(1) receptor-mediated bradycardia induced by NECA. 8-SPT and CGS 15943, antagonists at A(1), A(2A), and A(2B) but not A(3) receptors, inhibited the bronchoconstrictor response to adenosine. However, the degree of blockade (approximately 3 fold) did not reflect the plasma concentrations, which were 139 and 21 times greater than the K(B) value at the rat A(2B) receptor, respectively. Adenosine and NECA, but not CPA, CGS 21680 or 2-Cl-IB-MECA, induced contraction of parenchymal strip preparations from actively sensitized OA-challenged animals. Responses to adenosine could not be antagonized by 8-SPT or MRS 1754 at concentrations >50 times their affinities at the rat A(2B) receptor. The receptor mediating the bronchoconstrictor response to adenosine augmented following allergen challenge in actively sensitized BN rats cannot be categorized as one of the four recognized adenosine receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834616      PMCID: PMC1573180          DOI: 10.1038/sj.bjp.0704516

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

1.  Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.

Authors:  Y C Kim; M de Zwart; L Chang; S Moro; J K von Frijtag Drabbe Künzel; N Melman; A P IJzerman; K A Jacobson
Journal:  J Med Chem       Date:  1998-07-16       Impact factor: 7.446

2.  Further characterization of an adenosine transport system in the mitochondrial fraction of rat testis.

Authors:  A Jiménez; D Pubill; M Pallàs; A Camins; S Lladó; J Camarasa; E Escubedo
Journal:  Eur J Pharmacol       Date:  2000-06-09       Impact factor: 4.432

3.  Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.

Authors:  K N Klotz; J Hessling; J Hegler; C Owman; B Kull; B B Fredholm; M J Lohse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1998-01       Impact factor: 3.000

4.  A3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis.

Authors:  Z Gao; B S Li; Y J Day; J Linden
Journal:  Mol Pharmacol       Date:  2001-01       Impact factor: 4.436

5.  [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain.

Authors:  M F Jarvis; R Schulz; A J Hutchison; U H Do; M A Sills; M Williams
Journal:  J Pharmacol Exp Ther       Date:  1989-12       Impact factor: 4.030

6.  125I-4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor.

Authors:  T M Palmer; S M Poucher; K A Jacobson; G L Stiles
Journal:  Mol Pharmacol       Date:  1995-12       Impact factor: 4.436

7.  The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist.

Authors:  S M Poucher; J R Keddie; P Singh; S M Stoggall; P W Caulkett; G Jones; M G Coll
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

8.  A role for mast cells in adenosine A3 receptor-mediated hypotension in the rat.

Authors:  J P Hannon; H J Pfannkuche; J R Fozard
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

9.  Binding of the A1-selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes.

Authors:  R F Bruns; J H Fergus; E W Badger; J A Bristol; L A Santay; J D Hartman; S J Hays; C C Huang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-01       Impact factor: 3.000

10.  2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.

Authors:  H O Kim; X D Ji; S M Siddiqi; M E Olah; G L Stiles; K A Jacobson
Journal:  J Med Chem       Date:  1994-10-14       Impact factor: 7.446

View more
  10 in total

Review 1.  Adenosine signaling and the regulation of chronic lung disease.

Authors:  Yang Zhou; Daniel J Schneider; Michael R Blackburn
Journal:  Pharmacol Ther       Date:  2009-05-05       Impact factor: 12.310

Review 2.  Adenosine receptors and asthma.

Authors:  Constance N Wilson; Ahmed Nadeem; Domenico Spina; Rachel Brown; Clive P Page; S Jamal Mustafa
Journal:  Handb Exp Pharmacol       Date:  2009

3.  Contractile responses to adenosine, R-PIA and ovalbumen in passively sensitized guinea-pig isolated airways.

Authors:  Timothy J Martin; Kenneth J Broadley
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

4.  The receptor mechanism mediating the contractile response to adenosine on lung parenchymal strips from actively sensitised, allergen-challenged Brown Norway rats.

Authors:  Cedric Wolber; John R Fozard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-01-27       Impact factor: 3.000

5.  CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities.

Authors:  Alexandre Trifilieff; Thomas H Keller; Neil J Press; Trevor Howe; Peter Gedeck; David Beer; Christoph Walker
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

6.  The Quintiles Prize Lecture 2004. The identification of the adenosine A2B receptor as a novel therapeutic target in asthma.

Authors:  Stephen T Holgate
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

7.  Mast cell involvement in the adenosine mediated airway hyper-reactivity in a murine model of ovalbumin-induced lung inflammation.

Authors:  Daniel Wyss; Olivier Bonneau; Alexandre Trifilieff
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

8.  Airway hyperresponsiveness to adenosine induced by lipopolysaccharide in Brown Norway rats.

Authors:  B Tigani; J P Hannon; C Rondeau; L Mazzoni; J R Fozard
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

9.  Evidence for an atypical receptor mediating the augmented bronchoconstrictor response to adenosine induced by allergen challenge in actively sensitized Brown Norway rats.

Authors:  J P Hannon; B Tigani; C Wolber; I Williams; L Mazzoni; C Howes; J R Fozard
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

10.  Effects of immunomodulators on airways hyperresponsiveness to adenosine induced in actively sensitised Brown Norway rats by exposure to allergen.

Authors:  Bruno Tigani; Jason P Hannon; Elisabeth Schaeublin; Lazzaro Mazzoni; John R Fozard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-06-24       Impact factor: 3.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.